These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 23827351

  • 1. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC.
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [Abstract] [Full Text] [Related]

  • 2. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT, Kiladjian JJ, Hasselbalch HC.
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [Abstract] [Full Text] [Related]

  • 3. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H, Spivak JL.
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [Abstract] [Full Text] [Related]

  • 4. JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation.
    Sassi H, Menif S, Ammar SB, Farrah A, Othmen HBH, Amouri H.
    Pan Afr Med J; 2021 May; 39():194. PubMed ID: 34603575
    [Abstract] [Full Text] [Related]

  • 5. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N, Stacher E, Regitnig P, Zinke-Cerwenka W, Hojas S, Hubmann E, Porwit A, Bjorkholm M, Hoefler G, Beham-Schmid C.
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [Abstract] [Full Text] [Related]

  • 6. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2014 Sep; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 7. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 8. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
    Bai J, Xue YP, Zhang L, Li CH, Fan DM, Li B, Xu SC, Li DP, Sun XJ, Jiang B, Yang RC.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
    [Abstract] [Full Text] [Related]

  • 9. Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.
    Zhang Y, Zhou Y, Wang Y, Teng G, Li D, Wang Y, Du C, Chen Y, Zhang H, Li Y, Fu L, Chen K, Bai J.
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [Abstract] [Full Text] [Related]

  • 10. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL, Marton E, Plander M.
    Orv Hetil; 2011 Nov 06; 152(45):1795-803. PubMed ID: 22011365
    [Abstract] [Full Text] [Related]

  • 11. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
    Pedersen RK, Andersen M, Knudsen TA, Sajid Z, Gudmand-Hoeyer J, Dam MJB, Skov V, Kjaer L, Ellervik C, Larsen TS, Hansen D, Pallisgaard N, Hasselbalch HC, Ottesen JT.
    Cancer Med; 2020 Mar 06; 9(6):2039-2051. PubMed ID: 31991066
    [Abstract] [Full Text] [Related]

  • 12. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, Büsche G, Kreipe H.
    Exp Hematol; 2009 Oct 06; 37(10):1186-1193.e7. PubMed ID: 19616600
    [Abstract] [Full Text] [Related]

  • 13. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, Richie MA, Borthakur G, Konopleva M, Cortes J, Verstovsek S.
    J Clin Oncol; 2009 Nov 10; 27(32):5418-24. PubMed ID: 19826111
    [Abstract] [Full Text] [Related]

  • 14. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
    Berdeja J, Palandri F, Baer MR, Quick D, Kiladjian JJ, Martinelli G, Verma A, Hamid O, Walgren R, Pitou C, Li PL, Gerds AT.
    Leuk Res; 2018 Aug 10; 71():82-88. PubMed ID: 30025280
    [Abstract] [Full Text] [Related]

  • 15. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov 10; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 16. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C, Alvarez-Larrán A, Martínez-Avilés L, Mojal S, Longarón R, Salar A, Florensa L, Serrano S, Bellosillo B.
    Br J Haematol; 2011 Feb 10; 152(4):413-9. PubMed ID: 21219298
    [Abstract] [Full Text] [Related]

  • 17. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.
    Ann Hematol; 2007 Apr 10; 86(4):245-53. PubMed ID: 17262192
    [Abstract] [Full Text] [Related]

  • 18. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Dam MJB, Pedersen RK, Knudsen TA, Andersen M, Skov V, Kjaer L, Hasselbalch HC, Ottesen JT.
    Eur J Haematol; 2021 Dec 10; 107(6):624-633. PubMed ID: 34411333
    [Abstract] [Full Text] [Related]

  • 19. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Dec 10; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 20. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, Moliterno A.
    Br J Haematol; 2014 Jan 10; 164(1):83-93. PubMed ID: 24903629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.